Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced‐stage follicular lymphoma: A cost‐effectiveness analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|15|2637-2645

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.15, 2015-08, pp. : 2637-2645

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The cost‐effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite

A population‐based study of prognosis in advanced stage follicular lymphoma managed by watch and wait

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 3, 2015-05 ,pp. : 435-444

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced‐stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 544-551

John Wiley & Sons Inc

Access to resources Recommend Favorite

A French approach to cost-effectiveness analysis?

By Pouvourville Gérard  

The European Journal of Health Economics, Vol. 11, Iss. 6, 2010-12 ,pp. : 521-523

Springer Publishing Company

Access to resources Recommend Favorite

Cost‐Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 7, 2015-07 ,pp. : 947-955

John Wiley & Sons Inc

Access to resources Recommend Favorite